Diffusion Pharmaceuticals (NASDAQ:DFFN) Stock Rating Upgraded by ValuEngine

Diffusion Pharmaceuticals (NASDAQ:DFFN) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Wednesday, ValuEngine reports.

Shares of NASDAQ:DFFN opened at $0.43 on Wednesday. Diffusion Pharmaceuticals has a 1 year low of $0.21 and a 1 year high of $11.00. The business has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $1.89. The firm has a market capitalization of $2.67 million, a PE ratio of -0.07 and a beta of -0.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.52 and a quick ratio of 5.52.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its quarterly earnings results on Monday, November 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.11. Equities research analysts expect that Diffusion Pharmaceuticals will post -2.89 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Anson Funds Management LP purchased a new stake in shares of Diffusion Pharmaceuticals in the second quarter valued at approximately $933,000. Acadian Asset Management LLC purchased a new stake in shares of Diffusion Pharmaceuticals in the second quarter valued at approximately $48,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of Diffusion Pharmaceuticals in the second quarter valued at approximately $427,000. Hedge funds and other institutional investors own 14.41% of the company’s stock.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.

Further Reading: What does relative strength index mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.